In vivo effects of defibrotide on platelet c-AMP and blood prostanoid levels.
Patients were treated with defibrotide (3 X 200 mg/day) for 7 days. Plasma PGI2 and TXB2 levels were measured by RIA using EDTA-aspisol as anticoagulant and cyclooxygenase inhibitor. Isolated platelet c-AMP levels were also determined by RIA, using EDTA-dipyridamole as anticoagulant and phosphodiesterase inhibitor. Blood PGI2 levels were found to increase significantly upon treatment while the increase in TXB2 levels was not significant. Blood PGI2/TXB2 ratio increased 51%, 30 min after intravenous injection and it remained 28% higher during therapy than the predrug blood level. Significantly higher platelet c-AMP levels were also obtained after the injection of drug (0.02 less than p less than 0.05).
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D001161:Arteriosclerosis / Q000097:blood* / Q000188:drug therapy; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D000242:Cyclic AMP / Q000097:blood; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D008315:Malondialdehyde / Q000097:blood; D010974:Platelet Aggregation / Q000187:drug effects; D011089:Polydeoxyribonucleotides / Q000627:therapeutic use*; D011453:Prostaglandins / Q000097:blood*; D013929:Thromboxane B2 / Q000097:blood; D013997:Time Factors
D005343:Fibrinolytic Agents; D011089:Polydeoxyribonucleotides; D011453:Prostaglandins; C036901:defibrotide; D008315:Malondialdehyde; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D000242:Cyclic AMP